ROCKLAND, Mass., March 29, 2019 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada
Source: www.prnewswire.com
EMD Serono has received U.S. Food and Drug Administration (US FDA) approval for its drug Mavenclad (cladribine) tablets which are used to treat relapsing forms of multiple sclerosis in adults. This includes treatment for both the relapsing-remitting disease and active secondary progressive disease. Mavenclad is the first and only FDA-approved treatment for RRMS and active SPMS that provides two years of proven efficacy with a maximum of 20 days of oral treatment, during a two-year period.
